Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

516930

159992

159849

520690

159570

520880

513120

512290

513700

159506

159748

159316

520500

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

512010

562050

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng Health Care ETF(QDII)

TransThera reports promising tinengotinib results in advanced solid tumors

TransThera Sciences (Nanjing), Inc. presented new research at the 2026 AACR Annual Meeting, revealing that lineage plasticity from FGFR-JAK signaling contributes to endocrine therapy resistance in HR-positive breast cancer. Their study indicates that tinengotinib (TT-00420), a dual FGFR-JAK inhibitor, can restore luminal identity and resensitize resistant cancer models to endocrine therapy. This supports ongoing phase II trials of tinengotinib combined with endocrine therapy in advanced HR-positive breast cancer, highlighting its potential across various solid tumors and enhancing TransThera's position in the oncology market.

TransThera Showcases Tinengotinib Data on Endocrine Resistance in HR+ Breast Cancer at AACR 2026

The General Office of the State Council recently issued "Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals," reconstructing the price formation mechanism for drugs, proposing reform measures, and building a new pricing system aimed at making medications more accessible and reasonably priced for the public. This move has sparked a positive market reaction, with most stocks in the A-share innovative drug sector rising. The new policy will encourage high-level innovative drug research and development, promote price transparency for pharmaceuticals, prevent unreasonable bidding behaviors, and ensure that drug prices operate within a reasonable range

腾讯新闻 - 财经

[Editorial] Improve the Drug Pricing Mechanism to Make Medications More Affordable for the Public

02617

TRANSTHERA (Stock Code: 2617) conducted a placement today, raising approximately HKD 280 million, with a placement price of HKD 57.03, representing a discount of about 18% to the market price. The company expects no revenue in 2025, with a loss of approximately HKD 300 million. Research and development expenses for 2025 are projected to be HKD 247 million, with losses for the year increasing compared to the previous year. The company's asset situation shows non-current assets of HKD 45.05 million, current assets of HKD 500 million, and total equity of HKD 416 million

HKEX

AKESO

PHARMABLOCK

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

TRANSTHERA-B conducts a placement: raising HKD 280 million with no revenue in 2025, losing HKD 300 million

159622

159835

560900

The General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals," establishing a pricing governance logic for drugs centered on clinical value and innovation level. Experts indicate that this policy provides stable expectations and autonomous pricing space for the innovative drug industry, promoting industry profitability. In the first quarter, the total amount of external licensing transactions for innovative drugs exceeded USD 60 billion, and the innovative drug sectors in both the A-share and Hong Kong markets rebounded strongly. Despite the favorable policy, the contradictions between medical insurance payments and hospital usage still need to be resolved

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

CCB Principal CSI Innovative Drugs Industry ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

E Fund CSI Innovative Drugs ETF

GF CSI Innovative Drugs Industry ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI HK Equities Medical and Health Integration ETF

CITIC Securities Co., Ltd.

CITIC SEC

CICC

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value

159858

AACR and ASCO, two top academic conferences, are about to be held. The innovative drug sector is rising against the market correction, with the innovative drug ETF up over 1%. Improvement in macro liquidity and endogenous growth momentum within the industry are driving the valuation recovery of the sector. It is expected that more than 100 Chinese pharmaceutical companies will disclose nearly 400 research results at the AACR annual meeting, covering several popular technology areas. The market generally expects that excellent clinical results will enhance the valuations of related companies

China Southern CSI Brand Name Drug Industry ETF

With the AACR+ASCO dual conference approaching, the innovative drug sector has surged against the market trend

TransThera Sciences (Nanjing), Inc. plans to implement an H Share Award Scheme to enhance equity incentives for employees and service providers. This initiative requires shareholder approval and aims to improve talent retention and align stakeholder interests. The company will appoint a Scheme Administrator for operational matters and will issue a circular with more details. Shareholders are advised to exercise caution until the scheme is approved. TransThera Sciences is listed on the Hong Kong Stock Exchange under stock code 2617, focusing on biopharmaceutical innovations.

TransThera Sciences Proposes New H Share Award Scheme to Boost Equity Incentives

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF(159748.SZ)